Qingdao Baheal Medical INC. (301015) Fair Value & Analysis
Healthcare · CN · Market cap 10.6B CNY
Analysis
Qingdao Baheal Medical INC. (301015) currently trades at ¥19.81, while our model-based Fair Value estimate is ¥19.87 — implying the stock looks roughly 0.3% undervalued today. We read business quality at 90/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and the United Kingdom. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; liver disease drugs under the Fuzhenghuayu brand name; and urological drugs under the Betanli, Harle, and Wei Xi Kang brand names. It also provides ophthalmic drugs under the HYCOSAN brand name; tumor and other severe drugs under the Human Albumin and Xospata brand names; anti-aging and cosmeceuticals under the Quanis, Excellula, TRANSINO, and Qingchunbao brand names; diabetes drugs under the Naida, Feburic, and Naite brand names; respiratory and anti-infective products under the Klacid brand name; and medical nutrition under the Nutrasumma brand name. The company was incorporated in 2005 and is based in Qingdao, China. Qingdao Baheal Medical INC. is a subsidiary of BAHEAL Pharmaceutica…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.